

SYMPOSIUM AGENDA

Saturday, March 7, 2026
8:30 AM – 3:30 PM

8:30 – 9:30 AM	Registration, Breakfast, Exhibitors
9:30 – 9:45 AM	Welcome/Opening Remarks Noura Elsedawy, MBBCh
9:45 – 10:15 AM	Updates in Treatment of Diffuse Large B-Cell Lymphoma Alaa Altahan, MD
10:15 – 10:45 AM	Current Strategies in Management of T-Cell Lymphoma Muhammad Saad Hamid, MD
10:45 – 11:15 AM	Relapsed Refractory Multiple Myeloma: Personalization and Sequencing Noura Elsedawy, MBBCh
11:15 – 11:45 AM	CAR-T in Multiple Myeloma: Updates and Strategies for Outcome Optimization Brion Randolph, MD
11:45 – 1:15 PM	Lunch and Hematology Oncology Career Fair (non-CME)
1:15 – 1:45 PM	ASH 2025 MDS Updates Swapna Thota, MD
1:45 – 2:15 PM	ASH 2025 AML Updates Ashwin Kishtigari, MD
2:15 – 2:45 PM	CAR-T's for the Community Provider: Outpatient Therapy and Post Therapy Management Olalekan Oluwole, MD
2:45 – 3:15 PM	Case Reports from Memphis, Ask the Experts: An Open Case Discussion Noura Elsedawy, MBBCh, Moderator
3:15 – 3:30 PM	Closing Remarks Noura Elsedawy, MBBCh

HEMATOLOGY-ONCOLOGY CAREER FAIR

12:00 – 1:00 pm
Schreier Auditorium (lower level)
(non-CME)

These sessions are designed for medical students and internal medicine residents who are exploring training and career pathways in hematology and medical oncology. During these sessions, speakers will discuss various routes to fellowship training and highlight diverse career paths within the field. The sessions will provide ample opportunities for networking, mentorship, and collaboration with faculty and peers.

10:30 AM	Blood Buddies I: Mentoring and Career Advice Session
12:00 PM	Hematology-Oncology Fellowship: A Fellow's Perspective Srishti Sareen, MD Hematology-Oncology Chief Fellow
12:15 PM	How to Get Into a Hematology-Oncology Fellowship Swapna Thota, MD - Hematology-Oncology Fellowship Director
12:30 PM	Oncology Career Pathways in the Pharmaceutical Industry Chetasi Talati, MD - Senior Medical Director of Oncology Clinical Development - Abbvie
1:30 PM	Blood Buddies II: Mentoring and Career Advice Session
3:30 PM	Career Fair Raffle
3:45 PM	Social Networking Hour

REGISTRATION

Space is limited. Online registration is available at: <https://cenow.uthsc.edu/content/2026-hematology-symposium>
There is no cost to attend this symposium.



PARKING

Parking is available in the following garage:

- **Student Alumni Center (SAC) Garage (G lot)**
Madison Avenue west bound; turn right on Manassas Street and left into the parking garage behind the SAC
- **Street parking**
Available on the east and west side of Health Sciences Park along South Dunlap Street and Manassas Street



The University of Tennessee is an EEO/AA/Title VI/Title IX/Section 504/ADA/ADEA institution in the provision of its education and employment programs and services.

UT Health Science Center

ANNUAL UPDATES

in
**HEMATOLOGY
SYMPOSIUM**
2026

Saturday, March 7, 2026
8:30 AM – 3:30 PM

The University of Tennessee
Health Science Center
Student Alumni Center (SAC) & Gym
800 Madison Avenue
Memphis, TN 38163



OVERVIEW

The 2026 Annual Update in Hematology Symposium is designed to provide hematology and oncology providers with a state-of-the-art update on hematologic malignancies and blood disorders. It will tackle the latest scientific updates, innovative ideas, and timeliest questions related to the management and care of these challenging conditions. It is also designed to provide a networking opportunity for healthcare professionals, who care for patients with blood cancers and disorders in the Mid-South, to establish collaborative pathways to improve the management and outcomes of this patient population.

EDUCATIONAL OBJECTIVES

- Develop and execute personalized treatment plans for patients with hematologic malignancies and blood disorders by utilizing guideline recommendations based on the evaluation of molecular and phenotypic biomarkers, along with precise disease sub-classification.
- Assess the latest clinical trial data on novel agents and emerging strategies for newly diagnosed and relapsed or refractory disease states.
- Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts.

DESIRED OUTCOME

The goal of the 2026 Annual Update in Hematology Symposium is to provide participants with information to improve patient management and care strategies. This goal will be accomplished by discussing rapidly evolving developments and improved practice paradigms. The symposium will provide learners with enhanced knowledge of evidence-based data related to best practices for treating select blood cancers and disorders and inform them of the indications to refer patients for expert quaternary-level care. Panel discussions, along with question-and-answer sessions that include collaborative sharing of information and research, as well as networking with other healthcare professionals have shown to improve participant knowledge and competency. Additionally, it will build a connected community of hematologic care providers across the region.

FACULTY AND GUEST SPEAKERS



Alaa Altahan, MD
Assistant Professor
Division of Hematology/Oncology
UT Health Science Center



Noura Elsedawy, MD
Assistant Professor
Division of Hematology/Oncology
UT Health Science Center



Muhammad Saad Hamid, MD
Assistant Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine



Ashwin Kishtagari, MD
Clinical Research Fellow, Bick Lab
Assistant Professor
Department of Medicine, Division of
Hematology/Oncology
Vanderbilt University



Olalekan Oluwole, MD
Associate Professor
Division of Hematology/Oncology
Vanderbilt University



Brion Randolph, MD
Associate Professor
Division of Hematology/Oncology
UT Health Science Center



Swapna Thota, MD
Associate Professor
Division of Hematology/Oncology
UT Health Science Center

DISCLOSURE STATEMENT

The University of Tennessee College of Medicine is committed to providing CME that is balanced, objective, and evidence based. Individuals involved with planning, reviewing, and presenting content for this activity must disclose all financial relationships with ineligible companies within the past 24 months, regardless of the amount. The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals must disclose regardless of their view of the relevance of the relationship to the education. The UT College of Medicine, the CME staff, and Activity Director have taken appropriate steps to identify and mitigate relationships prior to the individuals assuming their roles.

4 CME / CEU credits provided



AMA Credit Designation:

The University of Tennessee College of Medicine (UTCOM) designates this live activity for a maximum of 4 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Education for Non-Physicians:

The UTCOM will issue Certificates of Participation to non-physicians for participating in this activity and designates it for CEUs using the national standard that 1 hour of educational instruction is awarded .1 CEU.

Accreditation:

The UTCOM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



TARGET AUDIENCE

Primary care physicians, hematologists, pathologists, medical oncologists, nurse practitioners, fellows, residents, medical students, and other healthcare professionals dedicated to treating blood cancers and disorders.

ACTIVITY MEDICAL DIRECTOR

Noura Elsedawy, MD
Assistant Professor
Division Hematology / Oncology
UT Health Science Center